Table 1.
Subject demographics
| Parameter |
Cancer (N = 81) | Benign (N = 130) | P Value | |
|---|---|---|---|---|
| Age (y) | Mean | 64 | 65 | .366 |
| Median | 63 | 65 | ||
| Range | (46–86) | (43–83) | ||
| Serum PSA (ng/mL) | Mean | 8.4 | 8.0 | .298 |
| Median | 6.2 | 6.6 | ||
| Range | (0.6–61.6) | (0.8–30.8) | ||
| DRE result (N, %) | Normal | 45 (55%) | 81 (62%) | .331 |
| Suspicious | 15 (19%) | 9 (7%) | ||
| N/A | 21 (26%) | 40 (31%) | ||
| Gleason sum(N, %) | 6 | 54 (66%) | ||
| 7 (3 + 4) | 15 (19%) | |||
| 7 (4 + 3) | 6 (7%) | |||
| 8 | 4 (5%) | |||
| 9 | 2 (3%) | |||
| Clinical stage (N, %) | T1c | 56 (69%) | ||
| T2a | 7 (9%) | |||
| T2c | 3 (4%) | |||
| N/A | 15 (18%) | |||
DRE, digital rectal examination; N/A, not applicable; PSA, prostate-specific antigen.